InflaRx (IFRX) Earnings Date & Reports

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

IFRX is expected to report earnings to rise 88.89% to -17 cents per share on May 07

Q1'25

Est.

$-0.17

Q4'24

Beat

by $0.16

Q3'24

Missed

by $0.05

Q2'24

Missed

by $0.04

Q1'24

Beat

by $0.02

The last earnings report on March 20 showed earnings per share of -9 cents, beating the estimate of -25 cents. With 367.28K shares outstanding, the current market capitalization sits at 88.62M.

View a ticker or compare two or three

Compare

IFRX